http://www.envita.com/ Stage 4 Colon Cancer has 5 stage.Stage 4 colon Cancer is the a lot of exhausted affliction stage.stage 4 colon Cancer has beat to abutting lymph nodes and added locations of the body. Common destinations accoutrement the alarmist and the lungs.

1. New Stage 4 Colon Cancer Alternative Cancer Treatment and
Natural Cancer treatment using Natural Killer Cells for Colon
Cancer
New Stage 4 Colon Cancer Alternative Cancer Treatment and
Natural Cancer treatment using Natural Killer Cells for Colon
Cancer
Immunotherapy: Powerful New Weapon Against Stage 4 Colon and Stage 4
Cancers With Advanced Natural Cancer Treatment and Alternative Cancer
Treatment
Immunotherapy is undisputedly an innovative premier medical strategy that relies on the
human immune system to conquer disease. Theoretically over the last 30 odd years,
extensive research conducted by teams of physicians and scientists has proven that
this venue is clinically successful for a wide range of diseases. Advances in adoptive
immunotherapy, which concentrates on the expansion and infusion of specific disease-
fighting white blood cells in patients, have boosted this science to peak performance in
terms of being an effective treatment for viral diseases, colon cancer, and even stage 4
cancer types.
As time goes by, we can expect to see the importance of immunotherapy grow,
particularly in late stage colon cancer, where patients experience metastasis and
targeting the cancer as it spreads becomes even more important. To date, stage 4
colon cancer is not much more than chemo and radiation. The statistics are so grim
that renowned care providers would not dare report survival data beyond the first couple
of years as it is more sobering than promising.

2. That being said, new immunotherapy treatments are bringing new hope as they deliver
a key part of the treatment puzzle - along with better results and quality of life for
patients.
Stage 4 Colon Cancer: Natural Killer and Natural Killer T Cells - Typically
Depressed in Stage 4 Colon Cancer Patients Data to Support Alternative Caner
Treatment and Natural Cancer Treatment
In a study1 of 102 colorectal cancer patients undergoing resections; 18 of them had
recurrences within two years of surgery. In all 18, there was significant evidence of
"significantly lower preoperative NK cytotoxicity than disease-free patients." Low
preoperative NK cytotoxicity was predictive of recurrence in this cohort of patients. 1
And in another study2 with nearly 200 subjects, 49 of which suffered with colon cancer in
addition to 149 healthy controls, it was observed that Natural Killer levels in colon
cancer patients were significantly lower than those of the healthy control group.
Moreover, it has been shown3 that untreated patients with colon cancer have
suppressed Natural Killer and Lymphokine-activated killer cells - particularly in late
stage patients. These patients were also found to have compromised interferon-gamma
producing activities.
NK cell activity serves as a strong prognostic factor for distant metastasis following
surgery for colon cancer. In a study4 with 140 colon cancer patients in curatively
operated stage I-III diseases, preoperative NK cell activity of 20 percent or less
correlated with poor survival. This lower NK activity was also associated with distant
metastases, while attenuated NK cell activity was a significant parameter for predicting
distant metastasis following curative surgery.
Further evidence5 suggests that pretreatment levels of NK cytotoxicity in patients are
significantly related to overall survival, progression-free survival, and response rate.
Moreover, it has also been observed that colon cancer patients who are 6 to 12 months
after tumor resection, have shown a rise in spontaneous, antibody-induced, and PHA-
induced cytotoxicity levels - significantly higher than those found in age-matched
controls of healthy individuals.
Sadly, conventional medicine has virtually ignored this type of immunotherapy ... until
now.
Astounding Progress in Treating Stage 4 Colon Cancer and Other Stage 4
Cancers with Proprietary Immunotherapy Breakthrough Alternative Cancer
Treatment and Natural Cancer Treatment
Recently, a bevy of researchers have touted the successful clinical use of natural killer
cells (NKs) and natural killer T cells (NKTs) in treating patients with various

3. malignancies.8,9 While NKs and NKTs are commonly found circulating in the body in
minimal amounts, they possess the ability to identify and kill both tumor cells and virally
infected cells, and are a major initial defense of our immune system. Without question,
patients with colon cancer and stage 4 cancers are often found to be deficient in
production of these powerful cells. Over the last 20 years, a number of studies have
described NK dysfunction in colon cancer patients.10-12
Specifically, NKs from these patients show a lesser ability to destroy tumor cells in
laboratory tests than NKs from healthy patients.10-12 NKs from later stage patients
were dramatically more dysfunctional compared to early stage patients with no
metastases.10,11 Further, NKs from patients with more advanced disease had an
impaired response to interferon, a major growth factor for NK cells.10 T lymphocytes
from such patients also do not respond well to stimulatory factors.12 The amount and
function of NKT cells have also been under investigation in colon cancer patients.13
NKT numbers in these patients were significantly reduced compared to healthy controls
and patients with other cancer types; further, NKTs in these patients were less
responsive to short-term stimulation, yet were still capable of substantial expansion.13
Such research cumulatively suggests that colon cancer patients experience an immune
suppression that worsens as disease progresses. However, cells with anti-tumor
activity can indeed be expanded from these patients for worthy use in clinical
immunotherapy regimens.
It is important to note that expansion of natural killer cells is not the same, in process or
effect, as taking a product or providing an intravenous nutrient or substance to increase
NK cells in the patient. Such methods are far inferior to the targeted, expansion method.
Natural Killer and Natural Killer T Cells are Depressed in Stage 4 Colon Cancer
Patients the data is clear Alternative Cancer Treatment and Natural Cancer
Treatment Provides Important Options
In a study1 of 102 colorectal cancer patients undergoing resections; 18 of them had
recurrences within two years of surgery. In all 18, there was significant evidence of
"significantly lower preoperative NK cytotoxicity than disease-free patients." Low
preoperative NK cytotoxicity was predictive of recurrence in this cohort of patients.1
And in another study2 with nearly 200 subjects, 49 of which suffered with colon cancer in
addition to 149 healthy controls, it was observed that Natural Killer levels in colon
cancer patients were significantly lower than those of the healthy control group.
Moreover, it has been shown3 that untreated patients with colon cancer have
suppressed Natural Killer and Lymphokine-activated killer cells - particularly in late
stage patients. These patients were also found to have compromised interferon-gamma
producing activities.
NK cell activity serves as a strong prognostic factor for distant metastasis following
surgery for colon cancer. In a study4 with 140 colon cancer patients in curatively

4. operated stage I-III diseases, preoperative NK cell activity of 20 percent or less
correlated with poor survival. This lower NK activity was also associated with distant
metastases, while attenuated NK cell activity was a significant parameter for predicting
distant metastasis following curative surgery.
Further evidence5 suggests that pretreatment levels of NK cytotoxicity in patients are
significantly related to overall survival, progression-free survival, and response rate.
Moreover, it has also been observed that colon cancer patients who are 6 to 12 months
after tumor resection, have shown a rise in spontaneous, antibody-induced, and PHA-
induced cytotoxicity levels - significantly higher than those found in age-matched
controls of healthy individuals.
This data begs the question why are NK cells and immune system considered vastly
more important to conventional cancer treatment protocols? It was questions like this
one that led Envita to develop a proprietary new treatment.
Envita Leads the Field in Stage 4 Colon Cancer and Stage 4 Cancer- Targeted
Immunotherapy Latest In Alternative Cancer Treatment and Natural Cancer
Treatment
Multitudes of published studies have demonstrated the effects of adoptive immune
therapy in cancer patients. Envita's renowned medical team assessed the best of these
studies and focused on the strengths and weaknesses of each. Their findings
established a protocol that incorporates only the best procedures for the expansion and
application of cells as a powerful immunotherapy. Our protocols are based on the most
recent published research in the field, from some of the most prestigious hospitals and
universities in the nation and around the world. However, our treatment has been
specially designed to deal specifically with colon cancer and stage 4 cancer patients'
immune systems. And the sooner this treatment method is administered to the patient,
the quicker improvements are experienced throughout the whole of their treatment.
Envita's Two-fold Stage 4 Colon Cancer and Stage 4 Cancer Immunotherapy
Alternative Cancer Treatment and Natural Cancer Treatment That Matte Most
Envita Natural Medical Center in its Mexico office is currently utilizing NK cells and
CTLs as immunotherapy Treatment for colon cancer and stage 4 cancer patients.
Envita's proprietary immune therapy vaccine is called AAIT (for autologous adoptive
immune therapy,) and there are 4 major cell types involved - the great majority being
natural killer cells and T cells. The types of cells that make up Envita's treatment are
listed below:
• Natural killer cells
• Natural killer T cells
• Cytokine-induced killer cells
• Cytotoxic T lymphocytes

5. The vaccine(s) is compiled by growing a patient’s own antitumor immune cells into the
billions. These cells are then analyzed for activation markers and tested for their ability
to kill colon cancer and other stage 4 cancer cells in the laboratory, then re-infused into
the patient.
Enhancing the immune system is a major benefit to fighting colon cancer or other
cancers, but this vaccine-driven immunotherapy routine may be added upon through
subtraction. Simply put, we can improve results by not only bolstering critical
components of the immune system, but simultaneously depleting it of negative factors
that impede its functionality. Depleting such negative factors is critical to a patient's
success.
It is no secret that cancer cells effect the release of T-regulatory cells, or "negative T
cells." The numbers of these cells correlate directly with specific cancer stages -
respective to each cancer type. The more advanced the cancer, the higher the T-
regulatory cells. These cells block your body’s system ability to fight. The immune
system is the first and last defense against cancer.
Naturally, by stepping in and acting to deplete these cells along with other key enzymes
that block critical immune system, cancer cell-killing action will be expedited
exponentially. Imagine your immune system being targeted and ready to go, yet
something in your body suddenly applies the brakes. This is in fact what most advanced
colon cancer and stage 4 cancer patients are dealing with in regards to high regulatory
T cells. Envita's immunotherapy treatment protocols build a targeted vaccine by using
the body's most powerful cancer killers, but also depletes the portion of the immune
system that inhibits the body from functioning efficiently in such regard.
Case in point, there is no treatment (conventional or alternative) that can be effective in
the later stages of cancer if these negative T-cells are not effectively down-regulated.
Unlike other available immunotherapy treatments, Envita’s AAIT can be used as a
stand-alone. AAIT can also be given in conjunction with other therapies that will act to
enhance the effects of cells once they are in the patient. This is a key improvement over
many of the published studies in the scientific literature. Envita’s AAIT therapy is not just
focused on expanding cells in the laboratory; the ultimate goal is to also expand them
and keep them activated after they are infused back into the body. Making AAIT next
important piece to colon cancer and stage 4 cancer therapy.
AAIT Immunology Available for Stage 4 Colon cancer and Stage 4 Cancer
Patients at Envita Mexico Leader in Alternative Cancer Treatment and Natural
Cancer Treatment
Envita Natural Medical Center is currently utilizing NK, NKT, and T lymphocytes as
supportive immunotherapy for our cancer patients. Envita’s therapy is titled AAIT, and
increases a patient’s own antitumor immune cells into the billions over a span of several
weeks. These cells are monitored for activation markers, evaluated for their ability to kill

6. cancer cells in the laboratory, and then subsequently re-infused into the patient.
Heralded by scientific research and clinical results, Enivta's AAIT immunotherapy offers
a potent option for cancer patients who are dedicated to battling stage 4 colon and other
stage 4 cancers while maintaining an intact immune system. Envita administers only
superior combinations of conventional and alternative cancer treatment bolstered by
advanced natural cancer treatment to help patients get healthier and improve their
overall quality of life.
1. Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of
natural killer cytotoxicity in patients with colorectal cancer. Arch Surg. 1987
Nov;122(11):1264-8.
2. Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granular
lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg.
1983 Aug;198(2):192-9.
3. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M.
Preoperative natural killer cell activity as a prognostic factor for distant metastasis
following surgery for colon cancer. Dig Surg. 2003;20(5):445-51. Epub 2003 Jul 31.
3. Matsunaga H, Kuwahara Y, Kusugami K, Morise K, Shimokata K. Natural killer,
lymphokine-activated killer and interferon-gamma producing activities of peripheral
blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer.
Gastroenterol Jpn. 1988 Oct; 23(5):527-33.
4. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M.
Preoperative natural killer cell activity as a prognostic factor for distant metastasis
following surgery for colon cancer. Dig Surg. 2003;20(5):445-51. Epub 2003 Jul 31.
5. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE.
Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma
patients treated with the monoclonal antibody 17-1A. Int J Cancer. 2003 Jul
10;105(5):717-23.
6. Waller CA, Gill PG, MacLennan IC. Enhancement of lymphocyte-mediated
cytotoxicity after tumor resection in patients with colorectal cancer. J Natl Cancer Inst.
1980 Aug;65(2):223-30.